The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The dollar fell against a basket of currencies, after President Trump said he would nominate Stephen Miran to temporarily join the Federal Reserve's board of governors. "Miran has expressed skepticism ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Trump tweets trigger major stock swings for companies like Tesla, Boeing, Pfizer. Democrats demand an investigation.

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the first ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...

Pfizer will report its fiscal second-quarter earnings on Aug. 5. Although we won't know if it'll continue its beats streak ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a ...